Cedilla Therapeutics Unveils Lead Programs for the Conditional Inhibition of TEAD and CDK2, Two High Value and Historically Undruggable Cancer Drivers

  /  

Cedilla Therapeutics Unveils Lead Programs for the Conditional Inhibition of TEAD and CDK2, Two High Value and Historically Undruggable Cancer Drivers

–Conditional modulation of proteins in their functional state opens a new dimension in precision oncology–

–IND-enabling studies expected to initiate in 1H 2022 for TEAD program and in 2H 2022 for CDK2 program–

CAMBRIDGE, Mass., October 21, 2021 – Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today revealed its two lead conditional inhibitor programs: an inhibitor of TEAD for the treatment of solid tumors, such as mesothelioma and certain squamous cell carcinomas; and a highly selective inhibitor of CDK2 for the treatment of multiple tumor types, including CDK4/6-resistant breast cancer, ovarian, uterine, stomach, and esophageal cancers. Both programs are wholly owned by Cedilla. In addition, Cedilla is pursuing discovery research efforts against a portfolio of high value cancer targets.

“Over the past three years, we have built an integrated suite of capabilities that enable us to understand the relevant functional states of important yet elusive cancer targets, and identify previously unrecognized small molecule binding sites,” said Alexandra Glucksmann, Ph.D., President and Chief Executive Officer of Cedilla Therapeutics. “Today, we are excited to announce our two lead programs from our internal efforts to discover conditional inhibitors: an inhibitor of TEAD and a highly selective inhibitor of CDK2. We look forward to advancing these programs closer to the clinic and creating novel medicines with the potential to deliver profound benefit to patients.”

The discovery of both programs was enabled by Cedilla’s novel approach to developing small molecule conditional inhibitors. Cedilla recognizes proteins as dynamic entities, whose function is orchestrated by inter-molecular associations and post-translational tailoring. By accounting for the native full-length protein with relevant post-translational modifications, protein-protein interactions and sub-cellular localization, Cedilla is able to understand proteins in their functional state to discover new ways to access key cancer drivers that have been considered undruggable.

“Since our founding, we have worked to develop a deep understanding of high-value, historically inaccessible targets, and to identify new vulnerabilities that may enable us to drug them more effectively, delivering superior clinical benefit,” said Brian Jones, Ph.D., Chief Scientific Officer. “Based on preclinical data, I believe our TEAD and CDK2 programs have clear advantages relative to historical approaches, offering the opportunity for preferential clinical utility, in terms of targeted efficacy or combinability with other therapeutic mechanisms. We look forward to advancing both programs into IND-enabling studies next year.”

About Cedilla’s TEAD Program

TEAD (transcriptional enhanced associate domain) is a key component of the Hippo signaling pathway that is aberrantly regulated in solid tumors such as mesothelioma and certain squamous cell carcinomas. TEAD is also increasingly implicated in resistance to targeted therapies, including those for the treatment of EGFR-mutated and KRAS-mutated lung cancer.

Cedilla’s program is designed to inhibit the function of TEAD by preventing a post-translational modification required for full function. The company’s portfolio of TEAD inhibitors encompasses multiple chemotypes with different effects on TEAD isoforms and cofactors, providing Cedilla a range of starting points for selecting a candidate with an optimal profile for effective and combinable TEAD inhibition. Cedilla plans to be conducting investigational new drug (IND) application-enabling studies in the first half of 2022.

About Cedilla’s CDK2 Program

CDK2 (cyclin dependent kinase 2) has been a major target of interest for cancer indications driven by amplification or high levels of Cyclin E, including in roughly half of patients with CDK4/6-resistant breast cancer. In addition, Cyclin E amplification drives genetically defined subsets of ovarian, uterine, stomach and esophageal cancers. The CDK2-Cyclin E cancer node has remained inaccessible due to challenges achieving selectivity over other CDKs (cyclin dependent kinases), particularly CDK1, and Cyclin E isoforms.

Cedilla has developed a unique series of inhibitors that bind to a previously unreported site on the CDK2-Cyclin E complex with unprecedented selectivity, potentially offering a substantial advance over two decades of industry efforts. Preclinical characterization suggests that the exquisite selectivity of Cedilla’s inhibitor could result in a better safety profile compared to traditional kinase inhibitors, particularly with respect to dose-limiting hematological toxicities. Cedilla plans to be conducting IND application-enabling studies in the second half of 2022. In addition, based on its unique insights into Cyclin biology, Cedilla has the potential to pursue additional drug discovery programs against related targets.

About Cedilla Therapeutics

Cedilla Therapeutics is bringing a new dimension to precision oncology. We have discovered new ways to selectively inhibit oncogenic drivers with small molecules that conditionally modulate proteins in their functional state. Our conditional inhibitors are unlocking critical and elusive cancer targets including TEAD and CDK2. We are a driven and patient-focused team. Follow our journey at www.cedillatx.com and LinkedIn.

Investor Contact:
Hannah Deresiewicz
Stern Investor Relations, Inc.
hannah.deresiewicz@sternir.com

Media Contact:
Amanda Houlihan
MacDougall
cedillatx@macbiocom.com

IT Engineer

IT Engineer

We are a close-knit, driven, and patient-focused team of drug discovery and precision oncology experts bringing a new dimension to precision oncology. We have discovered new ways to selectively inhibit oncogenic drivers with small molecules that conditionally modulate proteins in their functional state. Our conditional inhibitors are unlocking critical and elusive cancer targets including TEAD and CDK2.

You are an experienced IT Engineer exceptional problem-solving and customer service skill. Curiosity, flexibility, personal motivation, and drive are key attributes for all members of our team. 

We view you as a key contributor whose contributions will be critical to our success. Your role will include: 

  • Being the primary contact for day-to-day IT activities including troubleshooting support, meeting preparations and the onboarding and offboarding of users 
  • Elevating the organization’s understanding of IT policies and systems by training end users on the effective use of technology 
  • Managing the implementation of new technology and services across the organization 
  • Assisting the Head of IT/Informatics to identify optimal solutions by defining business requirements, priorities, best-in-class vendors and partners to work with 
  • Gathering feedback and sharing learnings with IT and the broader organization to continually improve support 

Some of the highlights of your background are

  • BA/BS, Information Technology or a similar field preferred 
  • 2-5 years of experience as a customer support engineering or technical support role 
  • Must have exceptional problem-solving, customer service, time management, organizational, and prioritization skills 
  • Experience with Windows, Mac and Linux (any distros), O365, VMware and familiarity with general enterprise and office software 
  • Proponent of change management and thorough documentation 
  • Experience with GxP environments, AWS and Azure, WAN/LAN and CISCO Meraki are pluses 
  • Experience with IT project management is a big plus 

To apply, please submit your resume to careers@cedillatx.com 

Associate Director / Director, Preclinical Project Management

Associate Director / Director, Preclinical Project Management

We are a close-knit, driven, and patient-focused team of drug discovery and precision oncology experts bringing a new dimension to precision oncology. We have discovered new ways to selectively inhibit oncogenic drivers with small molecules that conditionally modulate proteins in their functional state. Our conditional inhibitors are unlocking critical and elusive cancer targets including TEAD and CDK2.

You are a drug discovery scientist with experience leading program management for late lead optimization through IND-filing. As the Preclinical Project Manager you will work with preclinical project teams and scientific leadership, helping to develop, drive and coordinate project strategy and execution. Ideally with a scientific drug discovery background, you would draw on successful project management experience, obtained in a biotech or pharma setting. Intellectual and scientific curiosity, flexibility, personal motivation and drive are key attributes for all members of our team.

We view you as a key leader/scientist in the company, whose contributions will be critical to the success of our endeavor. Your role would include:

  • Leads program management activities for late lead optimization through development candidate selection, preclinical development and IND-filing.
  • Supports the project leaders and the project team in the development of the program strategy for selection of the development candidate and progression into clinical development, by planning and tracking activities in late lead optimization, pre-clinical development, through IND filing.
  • In support of project leaders, create integrated development plans, develop and analyze program strategies/costs/risks and revise plans accordingly. Identify, track, and support resolution efforts for all program-related issues.
  • Collaborate with Clinical Operations, Clinical Development and Regulatory Affairs around IND preparation to ensure team-based approach with efficient workflow.
  • Facilitate resolution of conflicts between functional groups while maintaining objectivity
  • Builds team spirit and positive team environment.
  • Mentor, supervise and encourage development of scientists working in pre-clinical development.

Some of the highlights of your background are:

  • 10+ years of relevant biotech or pharmaceutical industry experience.
  • 3+ years in a program management role. Hands on experience in leading program management activities for programs in preclinical development.
  • Strong scientific background in Biology, Chemistry, or other area of drug discovery or clinical development. Postgraduate degree in the sciences a plus.
  • Oncology experience strongly preferred.
  • Able to handle complexity and ambiguity as well as be able to prioritize effectively
  • Demonstrated ability to lead by influence, cross-functionally.
  • Must have the ability to motivate others, prioritize multiple tasks, and maintain positive interpersonal skills.
  • Must be able to clearly communicate complex program information in formal and informal settings.
  • Good conflict resolution and problem-solving skills are a must.
  • Experience setting and maintaining budgets.
  • Knowledge of project management tools (GANTs, Excel, etc.).

*To apply, please submit your resume to careers@cedillatx.com

Senior Scientist, Chemical Biology

Senior Scientist, Chemical Biology

We are a close-knit, driven, and patient-focused team of drug discovery and precision oncology experts bringing a new dimension to precision oncology. We have discovered new ways to selectively inhibit oncogenic drivers with small molecules that conditionally modulate proteins in their functional state. Our conditional inhibitors are unlocking critical and elusive cancer targets including TEAD and CDK2.

You are an experienced scientist with hands-on expertise in chemical biology and strong desire for executing on strategies aimed to identify and characterize novel ways to drug difficult targets working closely with other Cedilla scientists. As a Chemical Biology Senior Scientist you will join our growing team as a key contributor to Cedilla’s strategy to “putting proteins in context”. You will develop and use chemical biology probes and workflows to explore the diverse proteoform pool and interactome for selected proteins of interest, in relevant biological context, to identify opportunities for therapeutic intervention.

We view you as a thoughtful scientific leader in the company, whose contributions will be critical to the success of our endeavor. Those contributions include:

  • Designing chemical biology strategies, conducting experiments and interpreting complex data to investigate the effect of the cellular context on protein function.
  • Identifying and characterizing protein-ligand and protein-protein interactions (PLIs and PPIs) and post-translational modifications (PTMs) using state-of-the-art methods.
  • Participating on multi-disciplinary teams, collaborating with colleagues in biochemistry, biophysics and cell biology to answer key scientific questions that support the selection and enablement of high value drug targets, and to characterize the mechanism of action (MoA) and in-cell engagement of small molecules. 
  • Working closely with external partners to complement in-house capabilities.

Some of the highlights of your background are:

  • Expertise in bio-compatible and biorthogonal synthetic chemistry methods and principles for structure-activity relationship (SAR) optimization applied towards the design and selection of chemical biology probes for protein labeling, residue mapping and activity-based proteomics.
  • Proven track record in the implementation of diverse chemical biology and chemo-proteomics workflows and experiments applied to study PLIs and PPIs. Hands-on experience using proximity-based labeling (such as BioID or APEX), chemically-induced proximity (CIP) and activity-based proteomic profiling (ABPP) methods are highly desirable.
  • General understanding of quantitative high-resolution MS workflows with hands-on experience in sample preparation are preferred.
  • Creative and independent scientific thinking to solve complex technical and scientific problems. Capable of integrating information generated from multiple sources to shape and strengthen experimental design and research hypotheses.
  • Highly self-motivated, with excellent attention to detail and strong organizational and communication skills. Ability to work independently, yet team-oriented and capable of mentoring junior team members, building strong relationships with peers, customers and partners/collaborators.
  • Ph.D. or equivalent with 6+ years of industry applied experience, with a focus on chemical biology.

*To apply, please submit your resume to careers@cedillatx.com

Senior Scientist, Proteomics

Senior Scientist, Proteomics

We are a close-knit, driven, and patient-focused team of drug discovery and precision oncology experts bringing a new dimension to precision oncology. We have discovered new ways to selectively inhibit oncogenic drivers with small molecules that conditionally modulate proteins in their functional state. Our conditional inhibitors are unlocking critical and elusive cancer targets including TEAD and CDK2.

You are an experienced scientist with hands-on expertise in proteomics and strong desire for executing on strategies aimed to identify and characterize novel ways to drug difficult targets working closely with other Cedilla scientists. As a Proteomics Senior Scientist you will join our growing team as a key contributor to Cedilla’s strategy to “putting proteins in context”. You will develop and use MS proteomics methods to explore the diverse proteoform pool and interactome for selected proteins of interest, in relevant biological context, to identify opportunities for therapeutic intervention.

We view you as a thoughtful scientific leader in the company, whose contributions will be critical to the success of our endeavor. Those contributions include:

  • Operating and maintaining our LC-MS platforms and establishing robust proteomic workflows to conduct experiments that investigate the effect of the cellular context on protein function.
  • Performing analysis and interpretation of complex quantitative proteomic data. Identifying and integrating relevant internal and external data and knowledge resources to enable data mining in biological context.
  • Identifying and characterizing protein-ligand and protein-protein interactions (PLIs and PPIs) and post-translational modifications (PTMs) using state-of-the-art methods.
  • Participating on multi-disciplinary teams, collaborating with colleagues in biochemistry, biophysics and cell biology to answer key scientific questions that support the selection and enablement of high value drug targets, and to characterize the mechanism of action (MoA) and in-cell engagement of small molecules. 
  • Working closely with external partners to complement in-house capabilities.

Some of the highlights of your background are:

  • Ph.D. or equivalent with 6+ years of industry applied experience, with a focus on proteomics.
  • Expertise in sample preparation (e.g. fractionation and labeling), protein isolation (e.g. enrichment), operating state-of-the-art LC-MS systems and processing, analyzing and interpreting proteomics data.
  • Proven track record in the implementation and optimization of quantitative high-resolution mass spectrometry (qHRMS) workflows applied towards the study of PLIs, PPIs and PTMs.
  • Prior experience in Top- or Middle-Down and targeted proteomics, are highly desirable.
  • Creative and independent scientific thinking to solve complex technical and scientific problems. Capable of integrating information generated from multiple sources to shape and strengthen experimental design and research hypotheses.
  • Highly self-motivated, with excellent attention to detail and strong organizational and communication skills. Ability to work independently, yet team-oriented and capable of mentoring junior team members, building strong relationships with peers, customers and partners/collaborators.  

*To apply, please submit your resume to careers@cedillatx.com

Cedilla Therapeutics Appoints Chris Bowden, M.D. to its Board of Directors

  /  

Cedilla Therapeutics Appoints Chris Bowden, M.D. to its Board of Directors

CAMBRIDGE, Mass., April 21, 2021 – Cedilla Therapeutics, a venture-backed preclinical biotechnology company developing novel small molecules for cancer and other diseases, today announced the appointment of Chris Bowden, M.D., to its Board of Directors.

“Chris brings tremendous industry experience to Cedilla, with more than two decades of oncology drug development leadership, having successfully brought multiple novel medicines to market,” said Alexandra Glucksmann, Ph.D., President and Chief Executive Officer of Cedilla Therapeutics. “His insights will be particularly valuable as we prepare to nominate our first two precision therapeutic oncology drug candidates. We look forward to his many contributions as we advance our lead programs and work to build a broad portfolio of small molecule medicines that can redirect the course of disease and deliver profound benefit to patients.”

Dr. Bowden joined Agios as Chief Medical Officer in May 2014, leading clinical development activities that resulted in the TIBSOVO® approvals for IDH1 mutation positive acute myeloid leukemia in the U.S. Prior to joining Agios, Dr. Bowden was vice president product development oncology, franchise lead (Signaling Group) at Genentech, Inc., a member of the Roche Group. During Dr. Bowden’s eight years at Genentech, he was responsible for the successful development of a number of novel targeted oncology medicines, including Zelboraf™ for patients with BRAF V600E positive melanoma and Tarceva™ for patients with EGFr activating mutation positive, non-small cell lung cancer. From 2003 to 2006, Dr. Bowden was the executive director for EMEA (Europe, Middle East, Africa) regions for Bristol-Myers Squibb. In this role, he led medical affairs strategies for cancer, immunology and pain medicines. Earlier, Dr. Bowden held positions of increasing responsibility in oncology clinical development at Pharmacia Corporation and Janssen Pharmaceutical, Inc. Prior to his industry experience, Dr. Bowden was on the oncology faculty at the University of Virginia Health Science Center where he participated in numerous industry and cooperative group trials. Dr. Bowden received his medical degree from Hahnemann University School of Medicine in Philadelphia followed by internal medicine training at Roger Williams Medical Center and the Providence VA Medical Center, Rhode Island. He completed his medical oncology fellowship at the National Cancer Institute Medicine Branch. Dr. Bowden is board certified in internal medicine and medical oncology, and he serves on the board of directors at Ziopharm Oncology Inc.

“This is an exciting time to join Cedilla’s Board of Directors,” said Dr. Bowden. “Cedilla’s unique approach to addressing undruggable targets, coupled with the team’s deep drug development expertise, has the potential to bring much needed therapies to patients. I look forward to working with the board and the management team to advance the next generation of targeted molecular therapeutics, with the goal of enabling even greater reach, precision and impact.”

About Cedilla Therapeutics

Cedilla Therapeutics is a private biotechnology company developing targeted novel small molecule therapeutics directed to unrecognized allosteric binding sites and uncovering novel ways to access key disease drivers. The company employs a target-centric approach and integrates a multidisciplinary set of tools to design novel drug discovery screens that recapitulate the relevant functional state of validated disease drivers that have, to date, eluded conventional therapeutic modalities. For more information, please visit www.cedillatx.com or follow us on LinkedIn.

Investor Contact:

Hannah Deresiewicz
Stern Investor Relations, Inc.
hannah.deresiewicz@sternir.com